In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

A key target for these therapies is a protein called CD19 found on the cancer cells," said study author Jianjun Chen, Ph.D., in a news release. Chen is also the director of the Center for RNA ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

In a first, scientists have designed immune cells that protect stem cell transplants from being rejected by the body — and they could someday open the door for a cure for diabetes. The new cells, ...

The resulting CD19-CAR T-cells were specifically activated ... 5 × 10 6 CAR T-cells were lysed and 10 μg of protein were separated on a 10% polyacrylamide gel. After blotting, membranes ...

CTEs contain multiple domains, with the simplest form comprising a protein target for a CAR T cell, for example the CD19 extracellular domain, linked to an antibody fragment that binds to a second ...

Sana revolutionizes treatments for diabetes, cancer, and autoimmune diseases. SANA has high cash burn and dilution risks. See ...

Tafasitamab binds to CD19, a protein on the surface of B-cells that is also targeted by three CAR-T therapies – Novartis' Kymriah (tisagenlecleucel), Gilead's Yescarta (axicabtagene ciloleucel ...